Posted by Michael Wonder on 29 Dec 2022
TG Therapeutics announces FDA approval of Briumvi (ublituximab-xiiy)
28 December 2022 - US commercial launch expected Q1, 2023.
TG Therapeutics today announced the US FDA has approved Briumvi (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
